HLB PANAGENE Co., LTD. develops products in the field of molecular diagnostics in South Korea. Its products include liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and polycythemia vera diseases. The company also offers products for cervical cancer, sexually transmitted, and extreme drug resistance diseases; and peptide nucleic acid products. The company was formerly known as Panagene Inc. and changed its name to HLB PANAGENE Co., LTD. in August 2023. HLB PANAGENE Co., LTD. was incorporated in 1976 and is based in Daejeon, South Korea.
Metrics to compare | 046210 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship046210PeersSector | |
---|---|---|---|---|
P/E Ratio | −29.1x | −5.0x | −0.5x | |
PEG Ratio | - | −0.09 | 0.00 | |
Price/Book | 1.2x | 2.7x | 2.6x | |
Price / LTM Sales | 6.8x | 6.6x | 3.2x | |
Upside (Analyst Target) | - | 0.0% | 42.0% | |
Fair Value Upside | Unlock | 10.7% | 6.6% | Unlock |